Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks
The Journal of Infectious Diseases · 16.08.2023 · 228 (4) · 391-401
DOI: 10.1093/infdis/jiad034 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 03.02.2023. Verfasst von Pengfei Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Mpox, Monkeypox, Sexual and Gender Minorities. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Netherlands Organization for Scientific Research, Dutch Cancer Society.
Abstract (Originalsprache)
Background
This study aims to comparatively analyze clinical features, treatment, and patient outcomes between the previous and the 2022 mpox (monkeypox) outbreaks.
Methods
Five bibliographic databases were searched for studies reporting clinical features, management, and patient outcomes of mpox. Systematic review and meta-analysis were performed.
Results
In total, 73 studies were included in the systematic review, of which 33 studies were subjected to meta-analysis. Previous outbreaks substantially affected children, whereas the 2022 outbreak primarily affected male adults, of which 94.66% (95% confidence interval [CI], 88.03–98.95) were men who have sex with men. Furthermore, 72.47% (95% CI, 51.04–89.71) reported high-risk sexual activity and the overall human immunodeficiency virus (HIV) prevalence was 37.65% (95% CI, 30.09–45.50). Skin lesions remain the typical symptom; however, their anatomic distribution differed. Systemic manifestations were common, but rectal pain was unique to the 2022 outbreak. The estimated overall fatality during past outbreaks in Africa was 4.61% (95% CI, 2.39%–7.35%), whereas 6.34% (95% CI, 3.35%–10.10%) of patients from the 2022 outbreak required hospitalization. Antiviral treatment, in particular tecovirimat, has been prescribed for a subset of patients, but the efficacy remains inconclusive.
Conclusions
These findings are important for better understanding the disease and guiding adequate response to mpox outbreaks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands.
- School of International Affairs and Public Administration, Ocean University of China, Qingdao, China.
ORCID-Profile: Qiuwei Pan
Förderung
- Netherlands Organization for Scientific Research
- Dutch Cancer Society
Zitieren
APA
Li, P., Li, J., Ayada, I., Avan, A., Zheng, Q., Peppelenbosch, M. P., de Vries, A. C., & Pan, Q. (2023). Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks. The Journal of Infectious Diseases, 228(4), 391-401. https://doi.org/10.1093/infdis/jiad034
Vancouver
Li P, Li J, Ayada I, Avan A, Zheng Q, Peppelenbosch MP, et al. Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks. The Journal of Infectious Diseases. 2023;228(4):391-401. doi:10.1093/infdis/jiad034
BibTeX
@article{Li2023,
author = {Li, Pengfei and Li, Jiajing and Ayada, Ibrahim and Avan, Amine and Zheng, Qinyue and Peppelenbosch, Maikel P and de Vries, Annemarie C and Pan, Qiuwei},
title = {Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks},
journal = {The Journal of Infectious Diseases},
year = {2023},
volume = {228},
number = {4},
pages = {391--401},
doi = {10.1093/infdis/jiad034}
}
EUVIMED